Drug Trial Radar · NCT04595565
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,332
Planned (sponsor's estimate)
Start
Oct 28, 2020
Primary completion
Mar 30, 2027
Study completion Mar 30, 2029
Sponsor
- Lead sponsor
- GBG Forschungs GmbHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Gilead Sciences; Austrian Breast & Colorectal Cancer Study Group; Spanish Breast Cancer Research Group (GEICAM); ETOP IBCSG Partners Foundation; Cancer Trials Ireland; UNICANCER
- First posted
- Oct 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase III, prospective, multi-center, randomized, open label, parallel group, study in patients with HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy with 1:1 allocation to: * Arm A: Sacituzumab govitecan (days 1, 8 q3w for eight cycles); * Arm B: treatment of physician´s choice (TPC, defined as capecitabine or platinum-based chemotherapy for eight cycles or observation. Treatment in either arm will be given for eight cycles. In patients with HR-positive breast cancer, endocrine-based therapy, which includes the use of CDK4/6 inhibitors, will be administered according to local guidelines. The start of endocrine therapy will be at the discretion of the investigator; however, it will be encouraged to start after surgery/radiotherapy in patients without additional cytotoxic agents. Adjuvant pembrolizumab can be given until the completion of radiotherapy before randomization. Within the study the use of pembrolizumab in patients with TNBC who received pembrolizumab as neoadjuvant therapy is allowed as monotherapy in the TPC arm, according to the approval of pembrolizumab in this setting.
Conditions
- HER2-negative Breast Cancer
- Triple Negative Breast Cancer
Interventions
CapecitabineDrug
2000 mg/m² day 1-14 q21 day cycle for eight cycles
CarboplatinDrug
AUC 5 q3w or AUC 1.5 weekly for eight 3 weekly cycles
CisplatinDrug
25mg/m3 weekly or 75 mg/m3 q3w
Sacituzumab govitecanDrug
10 mg/kg body weight on days 1, 8 q3w
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive disease free survival (iDFS) between patients treated with sacituzumab govitecan vs. treatment of physician's choice.Time frame: Assuming 3.25 years of recruitment with 12 months ramp-up and 42 patients per month at peak and 3 years of follow-up after the last patient in, 396 events will be needed and final analysis is expected 75 months after study start.
Locations
163 sites in 7 countries. Site status is shown where the registry gives one.
MUG - Univ.-Klinik f. Frauenheilkunde u. Geburtshilfe Graz
Graz, Austria
MUG - Univ.-Klinik f. Innere Medizin Graz
Graz, Austria
MUI - Univ. Klinik f. Frauenheilkunde Innsbruck
Innsbruck, Austria
Ordensklinikum Linz GmbH - BHS
Linz, Austria
TumorZentrum Kepler Uniklinikum Linz
Linz, Austria
LKH Salzburg - PMU
Salzburg, Austria
Universitätsklinikum St. Pölten
Sankt Pölten, Austria
MUW - AKH Wien
Vienna, Austria
MUW - Med. Univ.-Klinik AKH Wien
Vienna, Austria
Salzkammergut-Klinikum Vöcklabruck
Vöcklabruck, Austria
Klinikum Wels-Grieskirchen GmbH
Wels, Austria
Landesklinikum Wr. Neustadt
Wiener Neustadt, Austria
CHU UCL Namur/Site Sainte Elisabeth
Namur, Belgium
Institut de cancérologie de l'ouest (Angers)
Angers, France
Institut Sainte Catherine
Avignon, France
Clinique Tivoli Ducos
Bordeaux, France
Institut Bergonié
Bordeaux, France
CH Fleyriat
Bourg-en-Bresse, France
Centre François Baclesse
Caen, France
Centre Jean Perrin 5
Clermont-Ferrand, France
Centre Georges François Leclerc
Dijon, France
Centre Oscar Lambret
Lille, France
CHU de Limoges
Limoges, France
Centre Leon Berard
Lyon, France
Institut Paoli-Calmettes
Marseille, France
Institut régional du Cancer de Montpellier - ICM Val d'Aurelle
Montpellier, France
Hôpital privé du Confluent
Nantes, France
Centre Antoine Lacassagne
Nice, France
Institut Curie (Paris)
Paris, France
Centre Hospitalier de Pau
Pau, France
Hôpital Privé Des Côtes d'Armor- Centre CARIO-HPCA
Plérin, France
Institut Godinot
Reims, France
Centre Eugène Marquis
Rennes, France
Centre Henri Becquerel
Rouen, France
Gcs Rissa
Sarcelles, France
Institut de Cancérologie Strasbourg Europe-ICANS
Strasbourg, France
Institut Claudius Regaud IUCTO
Toulouse, France
CHU Bretonneau
Tours, France
Gustave Roussy Cancer Campus
Villejuif, France
Hämatologie-Onkologie im Zentrum MVZ GmbH
Augsburg, Germany
Showing 40 of 163 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.